ArticleEuropean journal of immunology2015
The expression of mouse CLEC-2 on leucocyte subsets varies according to their anatomical location and inflammatory state.
Article in European journal of immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 44 citations in OpenAlex.
- C-type lectin-like receptor 2 in platelets amplifies inflammation in rheumatoid arthritis.Research and practice in thrombosis and haemostasis · 2025Article
- One immune cell to bind them all: platelet contribution to neurodegenerative disease.Molecular neurodegeneration · 2024Review
- CLEC-2 Supports Platelet Aggregation in Mouse but not Human Blood at Arterial Shear.Thrombosis and haemostasis · 2022Article
- Necrotic reshaping of the glioma microenvironment drives disease progression.Acta neuropathologica · 2022Review
- Curcumin-Based Inhibitors of Thrombosis and Cancer Metastasis Promoting Factor CLEC 2 from Traditional Medicinal SpeciesEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases.International journal of molecular sciences · 2021Review
- MARCOBiomedicines · 2021Article
- Lymphatic blood filling in CLEC-2-deficient mouse models.Platelets · 2021Article
- Role of Podoplanin-Positive Cells in Cardiac Fibrosis and Angiogenesis After Ischemia.Frontiers in physiology · 2021Review
- The Role of CLEC-2 and Its Ligands in Thromboinflammation.Frontiers in immunology · 2021Review
- Stromal Cells in the Pathogenesis of Inflammatory Bowel Disease.Journal of Crohn's & colitis · 2020Review
- Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin.Hematology. American Society of Hematology. Education Program · 2019Review
- Podoplanin neutralization improves cardiac remodeling and function after acute myocardial infarction.JCI insight · 2019Article
- Podoplanin regulates the migration of mesenchymal stromal cells and their interaction with platelets.Journal of cell science · 2019Article
- Functional significance of the platelet immune receptors GPVI and CLEC-2.The Journal of clinical investigation · 2019Review
- CLEC2 and CLEC5A: Pathogenic Host Factors in Acute Viral Infections.Frontiers in immunology · 2019Review
- Glycoprotein VI in securing vascular integrity in inflamed vessels.Research and practice in thrombosis and haemostasis · 2018Article
- The podoplanin-CLEC-2 axis inhibits inflammation in sepsis.Nature communications · 2017Article
- Platelet CLEC-2 protects against lung injury via effects of its ligand podoplanin on inflammatory alveolar macrophages in the mouse.American journal of physiology. Lung cellular and molecular physiology · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
Abstract
Expression of mouse C-type lectin-like receptor 2 (CLEC-2) has been reported on circulating CD11b(high) Gr-1(high) myeloid cells and dendritic cells (DCs) under basal conditions, as well as on a variety of leucocyte subsets following inflammatory stimuli or in vitro cell culture. However, previous studies assessing CLEC-2 expression failed to use CLEC-2-deficient mice as negative controls and instead relied heavily on single antibody clones. Here, we generated CLEC-2-deficient adult mice using two independent approaches and employed two anti-mouse CLEC-2 antibody clones to investigate surface expression on hematopoietic cells from peripheral blood and secondary lymphoid organs. We rule out constitutive CLEC-2 expression on resting DCs and show that CLEC-2 is upregulated in response to LPS-induced systemic inflammation in a small subset of activated DCs isolated from the mesenteric lymph nodes but not the spleen. Moreover, we demonstrate for the first time that peripheral blood B lymphocytes present exogenously derived CLEC-2 and suggest that both circulating B lymphocytes and CD11b(high) Gr-1(high) myeloid cells lose CLEC-2 following entry into secondary lymphoid organs. These results have significant implications for our understanding of CLEC-2 physiological functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.